Houston-based Alpha Energy forms Alpha Energy International to acquire and modernise mature oil fields; Tennor provides $500 million funding facility
HOUSTON, US – Media OutReach Newswire – 2 October 2026 – Alpha Energy, the Houston-based oil and gas upstream company, has formed Alpha Energy International to lead its expansion outside the United States and has sold a 65% stake in the new company to Tennor Global LLC.
Tennor has agreed to arrange Alpha Energy International with a $500 million funding facility, allowing the venture to move quickly on acquisitions in selected countries, including Venezuela. Alpha Energy International will be responsible for all of Alpha Energy's future activities and investments outside the USA.
The new company will initially target mature producing fields and difficult-to-recover reserves. Alpha's leadership team will develop the assets and run operations, while Tennor, as majority shareholder, will support the venture through its network of relationships in the target countries.
Lars Windhorst, Founder of Tennor Global, said: "Alpha's team has a rare track record of turning around mature fields at scale, and we believe that expertise is exactly what many producing countries need today. Tennor's role is to open doors and provide the capital to move quickly. Together, we intend to build an international oil company focused on getting more from existing fields, working in partnership with host governments and national oil companies."
Thomas Reed, CEO of Alpha Energy International and founder of Alpha Energy, said: "The combination of Alpha's technical and operating expertise with Tennor's financial support and deep knowledge of key international markets provides the basis for a new type of international oil company.
"Our strategy is simple. More oil remains in existing conventional fields than has ever been produced, and since the late 1980s, improvements in technology and engineering have added more recoverable barrels from existing fields than the industry's total greenfield exploration success. Alpha is on a mission to acquire and modernise these legacy fields. Better recovery of the world's existing oil and gas resources is Alpha's fundamental value proposition, and with Tennor we have the reach and resources to act."
A team built on the Yukos turnaround
Alpha Energy has a thirty-year history of conventional reservoir development and operations across more than sixty fields, primarily on the US Gulf Coast and the shallow-water shelf of the Gulf of America. Its principals have also operated at scale internationally. The company's COO spent more than a decade in Venezuela, including operatorship of a producing joint venture on Lake Maracaibo at over 100,000 barrels of oil per day.
Mr Reed, who will run Alpha Energy International from Houston, has 35 years of oil and gas experience with Yukos, RusPetro, JKX and Texas Petroleum Investment Company. The COO has 35 years of operations experience with Yukos and Gazprom, among others, most recently with the Venezuelan joint venture. Chris Hopkinson, CTO, has 38 years in the upstream business, including senior positions at Shell, Yukos, BG Group and KazMunayGas.
All three built Alpha's proprietary Alpha Technical Center on their experience at Yukos, where the same performance engineering techniques added nearly one million barrels per day of production in four years with a net reduction in the total well count. The Technical Center covers subsurface evaluation, reservoir engineering, well design and facilities design.
Alpha Energy International will recover production by optimising asset performance from the wells up, using a value-driven technical limit approach and current technologies. The company works alongside national oil companies, training and handing over to local engineers as it goes.
Hashtag: #AlphaEnergy
The issuer is solely responsible for the content of this announcement.
About Alpha Energy
Alpha Energy is a Houston, Texas based oil and gas upstream company specialising in conventional reservoir development and operations. Over thirty years it has operated in more than sixty fields, primarily on the US Gulf Coast and the shallow-water shelf of the Gulf of America. Alpha Energy International, its majority-owned international arm, is responsible for all of the company's activities and investments outside the USA.
About Tennor Global
Tennor Global is a holding and private equity company focused on energy, energy technology and artificial intelligence. It takes majority and minority stakes in public and private companies and invests in public and private debt, targeting special situations where its entrepreneurial approach and sector expertise can create value quickly. Its diversified portfolio also spans technology, industrials, natural resources, media, entertainment and sports, retail and real estate.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
Five-year collaboration will build the technology, data, and delivery capabilities needed to translate genomic research into real-world healthcare applications under Singapore's National Precision Medicine programme.
SINGAPORE – Media OutReach Newswire – 2 October 2026 – Precision Health Research, Singapore (PRECISE), and AI & digital transformation company, Temus, signed a memorandum of understanding to establish a PRECISE-Temus Joint Innovation Centre (JIC), a five-year collaboration to support the technology, data, and delivery capabilities for Phase III of Singapore's National Precision Medicine (NPM) programme.
The signing took place at the Precision Health Partnerships in Singapore event, witnessed by Guest of Honour Mr Ong Ye Kung, Minister for Health and Coordinating Minister for Social Policies.
The JIC brings together PRECISE's leadership of Singapore's national precision medicine programme with Temus's vision-to-value with velocity approach to transformation. It will help translate precision medicine from research into practical applications by strengthening the digital infrastructure, operating models, and safeguards needed to manage genomic data securely and responsibly.
Supporting Phase III of NPM
NPM's Phase III, launched in November 2025, aims to sequence the genomes of about 10 per cent of Singapore's local resident population (450,000 residents) - and build evidence on how genomic information can be used responsibly in healthcare at population scale, while continuing to support research into health and disease.
"Phase III is not simply about sequencing more genomes. It is about ensuring that NPM Phase III can manage genomic data securely and responsibly, in ways that support both research and care. The Joint Innovation Centre gives us a practical way to develop the platforms we need, keep them current and ensure they continue to meet evolving needs in this fast developing field without compromising security or scientific quality," said Professor Patrick Tan, Executive Director of PRECISE.
The JIC builds on work that PRECISE and Temus have undertaken together since 2024, providing a proven foundation for the next phase of the partnership. This includes plans to build a secure genomics data infrastructure that handles around 13.6 petabytes of genomic data – scaling to more than 60 petabytes, cutting data-processing timelines from weeks to days, and generating genome-wide association results for 100,000 genomes. The work spans data pipelines, research platforms, and visualisation solutions.
Building on secure genomics infrastructure
The JIC aims to place this work within a longer-term operating model. Scientists and engineers will work together to develop shared platforms for processing and analysing whole-genome data efficiently, sustainably and securely. The centre will also help ensure that these platforms can be maintained and improved as programme needs evolve, rather than rebuilt for each new project.
The team will also establish structured processes and appropriate safeguards to assess and integrate emerging methodologies and technologies, including AI-enabled tools.
"Precision health is a powerful example of why technology alone is not the solution. The science is advancing at a rapid pace, and AI is giving us increasingly powerful tools, but that requires trusted data, strong engineering, appropriate safeguards and people who know how to make all of those pieces work together," said Sng Ren Yeong, Chief Executive Officer of Temus.
"We are honoured to deepen our partnership and support for PRECISE. Together, we can help turn scientific priorities into useful platforms scalably for researchers and practitioners, while building the talent and institutional capabilities needed to sustain that progress for Singapore over the long term."
Developing talent and delivery capability
Beyond enabling precision health and innovation, the JIC is expected to build specialist delivery capability development across Singapore's precision health ecosystem. In partnership with PRECISE, Temus plans to explore talent development pathways for specialist consultants and engineers in areas such as computational biology and bioinformatics specific to precision medicine and genomics. These specialists would work alongside research and technology teams to build practical expertise through live projects.
For Temus, the JIC also represents a significant healthcare application of its AI Foundry, one of the priority sectors under Singapore's National AI Impact Programme. Launched in May 2026 at ATxSummit with support from Digital Industry Singapore, the AI Foundry is hiring, developing and deploying 50 Singapore-based AI professionals in live enterprise projects, building production-grade AI assets, data pipelines, governance frameworks and human-in-the-loop systems for regulated and operationally complex environments.
Hashtag: #Temus #PrecisionHealth #Genomics
https://temus.com
The issuer is solely responsible for the content of this announcement.
About PRECISE
Precision Health Research, Singapore (PRECISE) leads the National Precision Medicine (NPM) programme, advancing genomics to improve health and grow Singapore's biomedical sector. Phase II sequenced 100,000 Singaporeans, while Phase III, in partnership with Singapore's three healthcare clusters, is evaluating how genomics can be integrated into clinical care responsibly.
PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS). NPM Phase II is supported by the National Research Foundation, Singapore under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734).
For more information, visit www.npm.sg.
About Temus
Temus helps public sector agencies and private enterprises transform how they work and serve citizens and customers with production-grade AI, cloud and application engineering, consulting and design, in line with Singapore's Smart Nation and National AI ambitions. Its work spans health, defence, financial services, education and government.
Established by Temasek in 2021, Temus is about 600-strong and anchored in Singapore with a growing regional presence.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
Left to Right: Mr Sng Ren Yeong, CEO, Temus; Mr Ong Ye Kung, Minister for Health and Coordinating Minister for Social Policies; Professor Patrick Tan, Executive Director, PRECISE
